Hepatitis B Virus News and Research

RSS

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Vertex Pharmaceuticals Incorporated today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.

16 Apr 2010

Interim results from Pharmasset's phase 2a combination study of PSI-7977 with Pegasys and Copegus for HCV

Pharmasset, Inc. announced today interim efficacy and safety results from its ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with Pegasys® (peginterferon alfa 2a) and Copegus® (ribavirin) in patients with hepatitis C virus (HCV) genotype 1 who have not been treated previously.

15 Apr 2010

Inovio Biomedical receives $2.8M grant to develop DNA vaccine for HCV

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company and its collaborators from Drexel University, Cheyney University, and the University of Pennsylvania have received a $2.8 million grant to develop a DNA vaccine to treat hepatitis C virus.

9 Apr 2010

IFN therapy for chronic hepatitis C must be individualized and optimized for efficacy

The efficacy of interferon (IFN) therapy depends on the hepatitis C virus (HCV) genotype, pretreatment viral load and early viral kinetics. Thus, IFN therapy must be individualized and optimized according to the virological and clinical status of each patient.

9 Apr 2010

Phase 1 SAD study of PSI-938 for HCV initiated

Pharmasset, Inc. announced today that dosing has initiated in a phase 1, single ascending dose study in healthy volunteers with PSI-938, a third generation purine nucleotide analog polymerase inhibitor of hepatitis C virus. Pharmasset recently filed an Investigational New Drug Application with the Food and Drug Administration.

8 Apr 2010

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

In a clinical trial known as PROVE 3 published in this week's New England Journal of Medicine, treatment with telaprevir-based regimens significantly increased rates of sustained viral response (SVR) in patients with genotype 1 hepatitis C virus (HCV) infection who did not achieve SVR with at least one prior course of pegylated-interferon and ribavirin therapy.

8 Apr 2010

Secretary of Health announces five health research grants to improve health of Pennsylvanians

Secretary of Health Everette James today announced five health research grants totaling approximately $20 million will be awarded from Pennsylvania's share of the national tobacco settlement for 2009-2010.

8 Apr 2010

Hepatitis C infection increases risk for developing kidney cancer

Physicians at Henry Ford Hospital have found that infection with the hepatitis C virus increases the risk for developing kidney cancer.

8 Apr 2010

PS-targeting antibodies can block HIV virus from entering into certain blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine -targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research.

6 Apr 2010

SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

Drug discovery company, SCYNEXIS, Inc. today announced that multiple abstracts related to the Company's cyclophilin inhibitor, SCY-635, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria, April 14-18, 2010.

6 Apr 2010

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research. The article titled "Anti-Phospholipid Human Monoclonal Antibodies Inhibit CCR5-Tropic HIV-1 and Induces β-Chemokines" is available online today and will be published in the April 12, 2010 edition of the Journal of Experimental Medicine.

5 Apr 2010

Liver function tests misinterpreted in majority of children's hospitals

New research led by physician-scientists at University of California, San Diego School of Medicine shows that the test most commonly used to screen pediatric patients for chronic liver disease is often incorrectly interpreted in many children's hospitals throughout the United States.

2 Apr 2010

T-cell cytolytic activity may be effective in clearing HBV infection

Co-infection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) poses a treatment challenge. In Western Europe and the United States, chronic HBV infection has been found in 6%󈝺% of HIV-positive patients and this co-infection is well known to be associated with increased liver-related morbidity and mortality. However, factors associated with HBV surface antigen (HbsAg) loss in HIV and HBV co-infected patients remain unclear.

31 Mar 2010

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Drug discovery company, SCYNEXIS, Inc. announced today that management will present an overview on the Company's lead anti-hepatitis C virus (HCV) candidate, SCY-635, at the upcoming Canaccord Adams' Hepatitis C Conference on Thursday, April 1, 2010 at 11:15 am ET at the Peninsula Hotel in New York City.

31 Mar 2010

Study finds rapid epidemiological shift in HAV infection in Korea

In Korea, there has been a rapid epidemiological shift in hepatitis A virus infection as a result of rapid economic development. The adult cases of acute hepatitis A have increased rapidly during the past 10 years due to the emergence of susceptible adults in Korea.

31 Mar 2010

Praxis extends patient recruitment services for international HCV study

Praxis, a company specializing in centralized patient recruitment for clinical research studies, is extending patient recruitment services to a top 20 pharmaceutical company for an international Hepatitis C Virus study. The study explores an investigational drug's effectiveness for this condition affecting almost 4 million Americans.

31 Mar 2010

Potential new target for treating HCV infection

A team of scientists including University of Utah researchers has discovered that binding of a potent inhibitor of the hepatitis C virus to the genetic material of the virus causes a major conformational change that may adversely affect the ability of the virus to replicate.

30 Mar 2010

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).

26 Mar 2010

New research may help advance treatment strategies for common liver disease

A research article published in the journal PloS Pathogens could lead to improvements in the production of vaccines for hepatitis A, the most widespread viral disease in the world.

26 Mar 2010

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Vertex Pharmaceuticals Incorporated today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010.

17 Mar 2010

Hepatitis B Virus News and Research

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

Interim results from Pharmasset's phase 2a combination study of PSI-7977 with Pegasys and Copegus for HCV

Inovio Biomedical receives $2.8M grant to develop DNA vaccine for HCV

IFN therapy for chronic hepatitis C must be individualized and optimized for efficacy

Phase 1 SAD study of PSI-938 for HCV initiated

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

Secretary of Health announces five health research grants to improve health of Pennsylvanians

Hepatitis C infection increases risk for developing kidney cancer

PS-targeting antibodies can block HIV virus from entering into certain blood cells

SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Liver function tests misinterpreted in majority of children's hospitals

T-cell cytolytic activity may be effective in clearing HBV infection

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Study finds rapid epidemiological shift in HAV infection in Korea

Praxis extends patient recruitment services for international HCV study

Potential new target for treating HCV infection

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

New research may help advance treatment strategies for common liver disease

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News